# Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

> **NCT06986382** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Stanford University** · enrollment: 14 (estimated)

## Conditions studied

- Crohn Disease

## Interventions

- **DEVICE:** CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System
- **DRUG:** Prednisone/Methylprenisolone
- **DRUG:** Palifermin
- **DRUG:** ATG
- **DRUG:** Clofarabine
- **DRUG:** Melphalan
- **RADIATION:** Total Body Irradiation
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06986382
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2037-07
- **Final completion:** 2040-07
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2025-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06986382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06986382, "Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06986382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*